Biomarkers are potentially powerful tools for use in research and regulation. Their derivation from biologic specimens collected from human subjects does, however, present many ethical implications. Ethical issues are relevant in almost each facet of human biomarker research studies: design, identification and recruitment of subjects, handling and use of the data, and interpretation and communication of results. Researchers also face a number of dilemmas when considering the use of human biologic specimens and new biomarkers. The mere fact that such markers are the result of measurements in human specimens gives the appearance of being more accurate than traditional sources of information such as questionnaires or environmental monitoring; yet, this may not always be the case. The meaning of the results of biomarker studies may be unclear because the purpose of the study is usually for research rather than clinical purposes. There generally are no established normal ranges for biomarkers and the interpretation of findings are often difficult. Researchers may not communicate these results to subjects or consider followup action because the task may be too difficult or undefined, or the reaction of the subject cannot be anticipated. A wide range of practices in this regard exists among researchers. Many questions remain unanswered about the use of biologic specimens. These include questions of ownership and access to specimens. Related to this is the question of whether specimens collected for one research purpose can be used for an entirely different research purpose. This is still an open question. Researchers and regulators may not be aware of the potential for biomarker information to affect the lives of subjects and their families without sufficient protection of personally identifiable data and regulation of its use. It is incumbent on researchers to consider these human subject questions whenever they are using human specimens or biomarkers. -Environ Health Perspect 103(Suppl 3): 69-74 (1995) 
Introduction
The use of human biologic specimens is integral to current advances in molecular epidemiologic research and biotechnologic development. In the environmental health field, biomarkers collected from human specimens are now being used to indicate exposure, disease, or susceptibility (1) . Studies involving biologic markers have the potential to involve a broad range of ethical, legal, and social issues. These studies are characterized by the actual collection of biologic specimens from individual subjects. Biomarker assays on human specimens have the potential to be powerful research tools that can enhance medicine and public health. The "social" power of biologic information should be considered, 4676 Columbia Parkway, Cincinnati, OH . Telephone (513) (513) 841-4486. however, before any biomarker data are collected or used (2) .
Some concerns associated with human biomarker research stem from misconceptions of investigators and the general public about the nature of biomarker research. An important misconception is that direct access to biologic material gives the impression, if not the reality, of being closer to the "truth" than studies using subject self-reports, environmental exposure measurements, or record review as key data sources. In some instances, biomarker data may be the most valid information; however, it can be subject to measurement, analytic, and interpretative errors. Even when biomarker data are valid, there is a range of problems in interpretation and in the use of the information that can significantly affect participants in research. From this, many observers have voiced concern that the information derived from biomarker research may be improperly used or have disastrous and unanticipated effects on study subjects, or segments of society, or both (2, 3) . Such potential misuse, however, is no reason to abandon this research. Rather, it should be seen as an alert to scientists and others concerned about biomarker research to take an active role in guarding against potential problems.
In this article, we will review the process of conducting research on human biomarkers and address the ethical issues that arise at each step in the process. Our goal is to illustrate some potential problems and stimulate dialogue among scientists on approaches to prevent them.
Design of Studies
The temporal design structure of biomarker research is important for identifying human subject issues. Therefore, as preface to the discussion of ethical concerns, it is useful to describe the three temporal types of study design: contemporary, future, and retrospective studies.
Contemporary studies are those in which the specimens are collected and assayed and the results disseminated within a relatively short period. These may be transitional (i.e., studies that validate a marker in the laboratory and in the field) or etiologic studies (4, 5) in scope, and cross-sectional, case-control, or casecohort in design.
Future studies are those that are either targeted or open-ended. In a targeted study subjects will be recruited over a long period
Environmental Health Perspectives and specimens may be stored or banked for years. The actual study purpose and, hence, the assays to be conducted are, however, known. In contrast, an open-ended study is one wherein specimens are banked because it is believed to be a good idea and a unique resource. Individual research projects will, however, be determined years after the actual specimen collection.
Retrospective studies have characteristics of both of these other types. They involve finding a bank of collected specimens, possibly collected for purposes other than the research originally anticipated, and linking specimen assay results with some health outcomes. For example, the JANUS bank in Norway has been collecting blood specimens for cancer research since 1973 (6 The banking and use of specimens also raise the question of ownership of specimens. Who has legal ownership of specimens or the products of specimens? The case where a clinician used a patient's specimens to develop, patent, and profit from a cell line illustrates how these matters are still unresolved (8, 9) . Other questions of access involve whether other scientists or even nonscientific interests, such as insurance companies or employers, can obtain access to banked specimens.
Privacy and Confidentiality
Biomarker information about individuals has been useful in individual and group quantitative risk assessments (10, 11) . This use has been described from the vantage of the clinician and researcher, and the information is gathered with the consent and concurrence of the subject. The subject consents to provide the specimens and corollary demographic and risk factor information, and hence, cooperates in the specified research. The subject generally does not consent or imply consent to distribution of the data in a way that identifies him or her individually to any other parties, such as employers, unions, insurers, credit agencies, lawyers, etc.
Dissemination or revelation of results beyond the explicit purposes for which specimens were collected intrudes on subjects' privacy. Inadvertent labeling of a subject as "abnormal" or as "in the extremes of a distribution of marker assay results" could have a potentially deleterious impact on the person's ability to obtain insurance, a job, or credit; it also could affect the person socially. The psychological impact is virtually unknown. Thus, as Nelkin and Tancredi (2) note, some union leaders are concerned that workers will bear a "genetic scarlet letter" that they will become "lepers" or "genetic untouchables."
Although the records of governmentsponsored or funded studies will be maintained according to the Privacy Act of 1974 (PL93-579), this does not ensure that records will never be disclosed. In studies conducted by academic, business, or labor researchers, standard practices to maintain privacy and confidentiality are generally followed (12 (14) . Hence, a 25% change in the group mean may mask a 50% decrease in a few subjects.
Although many studies involve biomarkers for which a normal range has not been established, the researcher should nonetheless provide some perspective on results for each subject. This could be accomplished by providing subjects with their results, indicating the group mean and range and those for any comparison group, and explaining the lack of a known normal range.
Interpreting studies that involve biologic markers and relaying the results to the study group pose a number of other dilemmas. One such dilemma arises because interpretation of results is often influenced by the tension between group effects and individual effects (15) . Research data may yield information on group risks but not indicate individual risk. This dilemma is characteristic of epidemiologic research and predates studies using biologic markers. One of the major potential advances of molecular epidemiology is the ability to obtain specific information that may be predictive of risks to individuals (11, 16 The discordance between the meaning of group and individual effects may be tempered if the limitations of the biomarker research are clearly communicated to the subjects prior to their participation and reinforced during the explanation of the results. Individuals participating in a "research" study may misinterpret the purpose of the study and believe it is a health study and the results will tell them whether or not they are "all right." Clearly, this misconception may frustrate the subjects and researchers in studies that assess only a marker's validity or that provide information useful in an epidemiologic, rather than a clinical, sense (18) . Nevertheless, some biomarker studies may identify potentially relevant clinical findings.
In most biomarker studies, typically only one or a few markers are used because of the wide variances in human biomarkers. A single marker assay rarely should be interpreted in isolation. On an individual basis, the findings should be confirmed by a repeat test given at some later date. Other confirmatory studies should be sought for group results. When possible, batteries of markers may provide a fuller picture than would be seen with one or a few markers (15) .
In studies that compare putatively exposed and nonexposed individuals, the results may indicate that exposure is continuing and that there is an exposureresponse relationship. Such a finding may trigger the need for the researcher to address this fact so that subjects can take preventive or remedial action. and affected parties may be needed to come to a consensus on the interpretation or at least on the range of interpretations and on possible followup actions. For these types of situations, the best approach may be the involvement of these parties at the conceptualization of the study and throughout the process, rather than only at the dissemination phase.
Communication to Control Subjects
Interpretation of biomarkers also needs to be assessed in terms of possible background of the biomarkers in the general population. Since biomarkers may represent exposures from various sources and by various routes, a baseline in people not exposed by the route or source of interest is important. For example, in a study of dioxin, serum levels were measured in the unexposed referent population. These data were invaluable in determining that, although the referent population was not exposed to occupational sources of dioxin, they all had low serum levels of dioxin, presumably caused by low-level environmental contamination (19) . Although it is still unresolved whether the low levels of dioxin in adults cause obvious adverse outcomes, control subjects will require some interpretation of what the data mean.
Similarly, in a study of hospital workers exposed to ethylene oxide, nonexposed control workers were found to have hydroxyethyl hemoglobin adducts (20) . This means that other exogenous and endogenous sources of hydroxyethyl moieties needed to be considered, and subjects were apprised of this fact.
Responsibilities for Action
Studies that indicate excess frequency of exposure markers may obligate researchers or authorities to address the source of exposure. For researchers, this may involve, at the least, speculation as to the nature of the source. For authorities, it may involve investigation and efforts to control exposure.
For markers of effect, the actions to be considered may be primary or secondary preventive ones. For example, a cytogenetic finding such as increased sister chromatid exchanges in a group of individuals, may trigger the kinds of environmental controls needed to address exposure even though these are nonspecific-effect markers. The markers may also trigger ongoing medical screening or monitoring for disease. If the marker is intermediate in the disease process and still reversible, interventions, such as chemoprevention, may be considered (21) .
Markers of susceptibility, such as a P450 genotype, are the most problematic with regard to what actions can be taken. Markers of susceptibility can be used in research as effect modifiers indicating there is interaction of two or more variables. Routine monitoring or testing for markers of susceptibility are not intended to diagnose manifest symptoms of illness or dysfunction; rather they are intended to discover the truth behind appearances, that is, to detect conditions that are latent, asymptomatic, or predictive of possible future problems (2) . The use of these tests in job placement, for example, can be discriminatory per se, as well as when they are correlated with various demographic characteristics. This can occur when a markers's frequency is predominantly found in ethnic or racial groups that historically have been discriminated against. Using biomarkers for genetic screening can create various ethical problems, and the many cautions have been discussed elsewhere (22) (23) (24) (25) .
Dilemmas for Researchers
Scientists like to think of gathering and interpreting data as being independent from the social and political context; but this is not always possible, especially for data from biologic monitoring of workers or community residents (for example, near a hazardous chemical source). In these and other instances where there are current controversies over health risks, communicating the results of such data cannot be separated from the use of the data (3). Dissemination of risk information from biomarker studies or routine biomonitoring can have implications for citizens' and employees' rights to privacy; confidentiality; and nondiscrimination with respect to employment, insurance, medical removal protection, and acceptability for loans. Hence, researchers must be aware of the social power of biologic information (2 New scientific developments will exacerbate many of the issues discussed here. The obstacles to understanding associations between genetic predisposition and disease are slowly evolving as the use of synthetic probes, the polymerase chain reaction, and automated DNA-sequencing machines increase the efficiency and lower the cost of large-scale use of assays in human populations (22) . With these innovations, the temptation to use tests or markers before they are validated (26) There is also the temptation to believe that finding a genetic polymorphism may explain human behavior and disease. This reductionist attitude occurs among scientists who find genetic explanations more attractive than complex "unmeasurable" social explanations (27) . The 
Conclusion
In conclusion, awareness of the social power of biologic information presents a tension for the research scientist using human specimens and biologic markers. This tension has been described in the publication, "On Being a Scientist" by the National Academy of Sciences (30) . Three themes are addressed in the report: the relationship between the "objective" and the "subjective" in scientific research, the social mechanisms within science that contribute to its authenticity; and, the wider social responsibility of the scientist. Although these questions have characterized science for centuries, they have particular relevance to the human subjects issues in specimen collection, analysis, and interpretation. Such research requires that scientists be both objective and subjective. They must be objective in determining the rationale for the research, in designing it, and implementing it. This includes accurate portrayal of risks and benefits to potential subjects during the recruitment and consent phase and in interpreting and communicating results. Researchers also need a certain amount of subjectivity in this process to adequately address concerns from the vantage of subjects and other interested sectors of society and to provide recommendations for preventive, remedial, or clinical action. The report "On Being a Scientist" (30) rejects the notion that objectivity is the result of eliminating subjectivity. Rather, it is the result of authentic subjectivity that is the result of researchers being attentive, intelligent, reasonable, and responsible with regard to the potential impact of their work (30) .
With this as a framework, many issues still need to be resolved. These include the use of specimens for purposes for which they were not collected, the extent of These cannot be left solely to ethicists and institutional review boards; scientists need to participate in the discussions and contribute their views and concerns.
